Investors of Tempus AI Facing Losses Urged to Join Class Action Lawsuit
In a significant development for investors of Tempus AI, Inc., a nationwide law firm, Bronstein, Gewirtz & Grossman, LLC, has announced the initiation of a class action lawsuit targeting the company. The suit aims to address alleged violations of federal securities laws, particularly focusing on concerns raised during the specified class period from August 6, 2024, to May 27, 2025.
The crux of the claims against Tempus revolves around reports suggesting that the company significantly inflated the value of numerous contract agreements, some of which had strong ties to related parties and included provisions that were either non-binding or self-funded. Additionally, these allegations implicated risks to the integrity of a critical joint venture with SoftBank, which appeared to facilitate dubious financial maneuvers, termed "round-tripping", aimed at fabricating revenue.
Further compounding the issues, the lawsuit points to questionable billing practices associated with Tempus's acquisition of Ambry, posing potential ethical dilemmas and sustainability concerns. Furthermore, AstraZeneca’s scaling back of its financial commitments to Tempus through a 'pass-through payment' arrangement has raised serious red flags about the health of the company’s core operations and its revenue outlook.
On May 27, 2025, these troubling disclosures triggered a precipitous decline in Tempus’s stock price, which plummeted by $12.67 per share, equivalent to a 19.23% drop. This decline moved the stock from a closing price of $65.87 per share to $53.20 the following day, marking a significant financial setback for investors.
The law firm is actively encouraging affected investors to consider joining the class action lawsuit. Interested parties can learn more about the lawsuit by visiting Bronstein, Gewirtz & Grossman’s official site at bgandg.com/TEM. Additionally, the firm has made it clear that there is no cost for joining this legal effort for investors, as it operates on a contingency basis. If successful, the attorneys will recoup their expenses and fees from the total recovery, ensuring that investors do not bear any upfront financial burdens.
For those who believe they might have a claim, the deadline to act is August 12, 2025. Interested investors are urged to reach out to Bronstein, Gewirtz & Grossman’s attorney, Peretz Bronstein, or Client Relations Manager, Nathan Miller, at 332-239-2660 to discuss their options.
Legal representation from Bronstein, Gewirtz & Grossman has been instrumental in securing substantial recoveries for investors in similar securities fraud cases across the nation. Their extensive experience and dedication to protecting investors have positioned them as a leading firm in class action lawsuits.
Talents in maintaining open communication have fostered strong relationships with clients, helping them navigate the complexities of legal proceedings with confidence. As the lawsuit progresses, investors are encouraged to stay updated via the firm's social media channels on LinkedIn, X, Facebook, and Instagram for further developments.
This situation underscores the importance of due diligence by investors when navigating the complexities of financial markets and the potential risks associated with investing in companies that may not fully disclose relevant information to their stakeholders.
The crux of the claims against Tempus revolves around reports suggesting that the company significantly inflated the value of numerous contract agreements, some of which had strong ties to related parties and included provisions that were either non-binding or self-funded. Additionally, these allegations implicated risks to the integrity of a critical joint venture with SoftBank, which appeared to facilitate dubious financial maneuvers, termed "round-tripping", aimed at fabricating revenue.
Further compounding the issues, the lawsuit points to questionable billing practices associated with Tempus's acquisition of Ambry, posing potential ethical dilemmas and sustainability concerns. Furthermore, AstraZeneca’s scaling back of its financial commitments to Tempus through a 'pass-through payment' arrangement has raised serious red flags about the health of the company’s core operations and its revenue outlook.
On May 27, 2025, these troubling disclosures triggered a precipitous decline in Tempus’s stock price, which plummeted by $12.67 per share, equivalent to a 19.23% drop. This decline moved the stock from a closing price of $65.87 per share to $53.20 the following day, marking a significant financial setback for investors.
The law firm is actively encouraging affected investors to consider joining the class action lawsuit. Interested parties can learn more about the lawsuit by visiting Bronstein, Gewirtz & Grossman’s official site at bgandg.com/TEM. Additionally, the firm has made it clear that there is no cost for joining this legal effort for investors, as it operates on a contingency basis. If successful, the attorneys will recoup their expenses and fees from the total recovery, ensuring that investors do not bear any upfront financial burdens.
For those who believe they might have a claim, the deadline to act is August 12, 2025. Interested investors are urged to reach out to Bronstein, Gewirtz & Grossman’s attorney, Peretz Bronstein, or Client Relations Manager, Nathan Miller, at 332-239-2660 to discuss their options.
Legal representation from Bronstein, Gewirtz & Grossman has been instrumental in securing substantial recoveries for investors in similar securities fraud cases across the nation. Their extensive experience and dedication to protecting investors have positioned them as a leading firm in class action lawsuits.
Talents in maintaining open communication have fostered strong relationships with clients, helping them navigate the complexities of legal proceedings with confidence. As the lawsuit progresses, investors are encouraged to stay updated via the firm's social media channels on LinkedIn, X, Facebook, and Instagram for further developments.
This situation underscores the importance of due diligence by investors when navigating the complexities of financial markets and the potential risks associated with investing in companies that may not fully disclose relevant information to their stakeholders.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.